Corpus Intelligence IC Memo — LONGLEAF HOSPITAL 2026-04-26 14:12 UTC
IC Memo — LONGLEAF HOSPITAL
Investment Committee Memorandum | LA | 139 beds | Grade C | EBITDA uplift $2.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LONGLEAF HOSPITAL

CCN 194022 | nan, LA | 139 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

LONGLEAF HOSPITAL is a 139-bed suburban community hospital in nan, LA with $36.6M in net patient revenue and a 33.0% operating margin. The hospital serves a payer mix of 4.6% Medicare, 12.7% Medicaid, and 82.7% commercial.

Thesis: Turnaround. Our ML models identify $2.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 33.0% to 40.3% (+736bps).

Net Revenue HCRIS$36.6M
Current EBITDA COMPUTED$12.1M
Operating Margin COMPUTED33.0%
Occupancy HCRIS85.9%
Revenue / Bed COMPUTED$263K
Net-to-Gross HCRIS35.6%
Distress Probability ML43.1%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
43
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 33.0% places it above the state median. Among 43 size-comparable peers (70-278 beds), the median margin is -4.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (70-278), prioritizing same-state peers. 43 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LONGLEAF HOSPITAL (Target)LA139$36.6M33.0%
CHILDRENS HOSPITALLA189$523.4M6.7%
BATON ROUGE GENERALLA251$445.5M-6.7%
ST. TAMMANY PARISH HOSPITALLA213$434.6M4.5%
OCHSNER LSU HEALTH SHREVEPORTLA273$395.6M-50.0%
OCHSNER MEDICAL CENTER - BATONLA171$371.4M-11.5%
TOURO INFIRMARYLA270$369.4M-3.7%
ST. FRANCES CABRINI HOSPITALLA268$363.0M2.3%
WOMANS HOSPITALLA228$345.8M-8.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$769K+210bp18mo
Cost to Collect4.5%2.5%$732K+200bp12mo
Denial Rate Reduction12.0%6.5%$725K+198bp12mo
A/R Days Reduction5200.0%3800.0%$445K+122bp9mo
Clean Claim Rate88.0%96.0%$23K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$769K
Cost to Collect
$732K
Denial Rate Reduction
$725K
A/R Days Reduction
$445K
Clean Claim Rate
$23K
Total EBITDA Uplift$2.7M
Current EBITDA$12.1M
+ RCM Uplift+$2.7M
Pro Forma EBITDA$14.8M
Current Margin33.0%
Pro Forma Margin40.3%
WC Released (1x)$1.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$18.6M$106.6M5.74x41.8%
Base (11x exit)10.0x11.0x$18.6M$123.3M6.64x46.0%
Bull Case9.0x11.0x$16.7M$138.2M8.27x52.6%
Bull (12x exit)9.0x12.0x$16.7M$155.7M9.31x56.2%
Bear Case11.0x10.0x$20.4M$87.1M4.26x33.6%
Bear (11x exit)11.0x11.0x$20.4M$102.4M5.01x38.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 43 hospitals with 70-278 beds
  • Same-state prioritization (n=44)
  • Comp margins: P25=-12.5% / P50=-4.9% / P75=2.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.